Abstract 17904: The Omega-3 Index is Inversely Associated With Blood Pressure in a Large Cohort of Young Healthy Adults
Introduction: Omega-3 fatty acids (n-3 FA) may have blood pressure (BP) lowering effects in untreated hypertensive and elderly patients. Yet, the effects of n-3 FA in an earlier stage, i.e. on the BP of normotensives and young healthy adults remain unknown. The Omega-3 Index (relative amount of EPA and DHA of total fatty acids in %) reliably reflects an individuals’ Omega-3 status. We hypothesized that the Omega-3 Index is inversely associated with BP levels in young healthy adults.
Methods: The present study is part of the GAPP study, a population-based cohort of healthy adults age 25-41y in the Principality of Liechtenstein. In particular, individuals with cardiovascular disease, known diabetes or a BMI >35 kg/m2 were excluded. The Omega-3 Index was determined from whole blood using gas chromatography. Conventional office and 24h BP measurements were assessed according to standard protocols. Multivariable linear regression models were adjusted for potential confounders (Table).
Results: Overall 2036 participants (median age 37y IQR 32; 40, 53% female) were included in this analysis, with a median Omega-3 Index of 4.58 (IQR 4.08; 5.25). Individuals in the highest Omega-3 Index quartile had a 4 and 2 mmHg lower systolic and diastolic BP compared to individuals in the lowest quartile. We found significant linear inverse relationships of the Omega-3 Index with all BP values assessed (Table). Per 1-unit increase in log-transformed Omega-3 Index fully adjusted β coefficients (95% CI) were -2.64 (-4.78; -0.51; p=0.02) for 24h systolic, -2.29 (-3.89; -0.68; p=0.005) for 24h diastolic BP, -3.15 (-5.52; -0.77; p=0.01) for systolic office and -2.17 (-3.97; -0.37; p=0.02) for diastolic office BP.
Conclusions: In conclusion, a higher Omega-3 Index is significantly associated with clinically relevant lower systolic and diastolic BP levels in young healthy individuals. Diets rich in n-3 FA (and supplementations) may become a strategy for primary prevention of hypertension.
Author Disclosures: M.G. Filipovic: None. S. Aeschbacher: None. M.F. Reiner: None. S. Stivala: None. S. Gobbato: None. N. Bonetti: None. M. Risch: None. L. Risch: None. C. von Schacky: Ownership Interest; Significant; Owner of Omegametrix GmbH. G.G. Camici: None. T.F. Luescher: None. D. Conen: None. J.H. Beer: None.
- © 2016 by American Heart Association, Inc.